David Flockhart

David A. Flockhart (1952–2015) was a Scottish medical researcher who was a leader in the field of personalised medicine.[1] He was especially known for his work on factors affecting the use of tamoxifen to treat breast cancer such as variability in the level of the CYP2D6 enzyme.[2][3]

References

  1. ↑ "In death, there is life", The Economist, 26 March 2016, p. 84
  2. ↑ "David Flockhart : Obituary", Edinburgh Evening News, 3 December 2015
  3. ↑ In Memoriam, David A. Flockhart PhD, MD, Indiana University Department of Medicine, 26 November 2015
This article is issued from Wikipedia - version of the Friday, March 25, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.